Health Trials

Haploidentical Stem Cell Transplantation

3

Review clinical trials related to Haploidentical Stem Cell Transplantation. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD). This study will enroll and treat up to 24 participants. Recruitment is expected to last for about 2 years and participants will be followed for an additional 2 years post-HCT.

Participants needed: 24
Trial details
Phase: Phase 1, Phase 2Age: 12-45Biological sex: AllType: InterventionalSponsor: Arkansas Children's Hospital Research InstituteUpdated: Jun 4, 2026Locations: 4
Eligibility criteria

History of stroke and/or vasculopathy, including evidence of asymptomatic cerebr... [+6]

Presence of an HLA-matched sibling who is willing and able to donate bone marrow... [+13]

Read more
Status: Not yet recruiting

Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Phase III comparative, open-label, randomized (1:1) trial designed to evaluate the efficacy of reducing the total dose of PTCy to 70 mg/kg on GREFS compared to the standard dose of 100 mg/kg, in patients undergoing haploidentical HSCT for the treatment of a hematological malignancy, two years after HSCT.

Participants needed: 180
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Assistance Publique - Hôpitaux de ParisUpdated: May 12, 2026Locations: 1
Eligibility criteria

Age ≥ 18 years [+4]

Karnofsky performance status < 70% [+21]

Read more
Status: Recruiting

BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation

A Phase IIb open label study evaluates the safety and efficacy of repeat doses of BPC2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following Haploidentical Stem Cell Transplantation (Haplo-SCT).

Participants needed: 50
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: BioPhoenix Co., Ltd.Updated: Nov 24, 2025Locations: 1
Eligibility criteria

Male or female ages ≥18 and ≤ 65 years. [+18]

Has had any other prior organ transplantation. [+15]

Read more